A Two-part, 12-week, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Participants with Migraine.

  • Hutton, Elspeth (Primary Chief Investigator (PCI))
  • Germaine, Jack (Project Manager)
  • Sabet, Arman (Chief Investigator (CI))
  • Mullen, Saul (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date17/09/2031/12/23

Keywords

  • Migraine
  • Clinical trial